Exam 4 - CNS and Neurodegenerative Diseases (Chapter Summary, Book
Drug List):
Study online at https://quizlet.com/_gvbj1k
1. Progressive neurodegenerative diseases such as Parkinson's, Alzheimer's,
____________ disease, _____________ disease, ___________ multiple sclerosis, amy-
___________, and ______________ _________ ___________ cur- otrophic lateral sclerosis
rently have no curative treatments
2. Pharmacotherapy is targeted to: slow disease progression
and manage symptoms to
achieve optimal quality of
life
3. PD is believed to be due to a loss of dopamine-producing,
_____________-_____________ neurons in the _____________ substantia nigra, basal
_______ area of the ________ _________, resulting in pro- ganglia, motor, balance
gressive loss of _________ control and __________ for the
patient
4. As the condition progresses, the management of PD multiple, different, in-
may result in ___________ agents being used, each with crease, dopamine, signal-
a _____________ mechanism of action, they typically ing, receptors
__________ the availability of ____________ or the signal-
ing of the dopamine _____________
5. AD is believed to result from ___________ neuronal cholinergic, beta-amyloid,
loss, which is likely due to the accumulation of tau, death
______-___________ plaques and/or _____ protein that re-
sults in neuronal cell ________
6. Acetylcholinesterase inhibitors (donepezil, galanta- inhibit, acetylcholine,
mine, and rivastigmine) are the mainstay of therapy synaptic cleft, impairment,
for AD, these agents _______ enzymatic breakdown of loss
______________, thus making more acetylcholine avail-
able in the ___________ ______ to address the cognitive
, Exam 4 - CNS and Neurodegenerative Diseases (Chapter Summary, Book
Drug List):
Study online at https://quizlet.com/_gvbj1k
_____________ related to the ______ of cholinergic neu-
ronal activity
7. Memantine, an NMDA receptor antagonist, is often acetylcholinesterase in-
combined with an: hibitor in the treatment of
moderate to severe AD
8. A variety of medications have been developed for MS many of these treat-
to manage and address the relapsing patient, howev- ments are infusions re-
er: quiring professional ad-
ministration and supervi-
sion
9. Most of the pharmacological treatments of MS: modify and inhibit some
immune responses, thus
increasing the risk for in-
fections
10. A 75-year-old man has moderate Parkinson disease. B. Levodopa, carbidopa,
His tremors and bradykinesia are no longer respond- and entacapone
ing to anticholinergic treatment. Which combination
of antiparkinsonian drugs is an appropriate treatment
plan?
A. Amantadine, carbidopa, and entacapone
B. Levodopa, carbidopa, and entacapone
C. Pramipexole, carbidopa, and entacapone
D. Ropinirole, carbidopa, and selegiline
11. Which drug used in the management of Parkinson B. Bromocriptine
disease may cause vasospasm?
A. Amantadine
B. Bromocriptine
Drug List):
Study online at https://quizlet.com/_gvbj1k
1. Progressive neurodegenerative diseases such as Parkinson's, Alzheimer's,
____________ disease, _____________ disease, ___________ multiple sclerosis, amy-
___________, and ______________ _________ ___________ cur- otrophic lateral sclerosis
rently have no curative treatments
2. Pharmacotherapy is targeted to: slow disease progression
and manage symptoms to
achieve optimal quality of
life
3. PD is believed to be due to a loss of dopamine-producing,
_____________-_____________ neurons in the _____________ substantia nigra, basal
_______ area of the ________ _________, resulting in pro- ganglia, motor, balance
gressive loss of _________ control and __________ for the
patient
4. As the condition progresses, the management of PD multiple, different, in-
may result in ___________ agents being used, each with crease, dopamine, signal-
a _____________ mechanism of action, they typically ing, receptors
__________ the availability of ____________ or the signal-
ing of the dopamine _____________
5. AD is believed to result from ___________ neuronal cholinergic, beta-amyloid,
loss, which is likely due to the accumulation of tau, death
______-___________ plaques and/or _____ protein that re-
sults in neuronal cell ________
6. Acetylcholinesterase inhibitors (donepezil, galanta- inhibit, acetylcholine,
mine, and rivastigmine) are the mainstay of therapy synaptic cleft, impairment,
for AD, these agents _______ enzymatic breakdown of loss
______________, thus making more acetylcholine avail-
able in the ___________ ______ to address the cognitive
, Exam 4 - CNS and Neurodegenerative Diseases (Chapter Summary, Book
Drug List):
Study online at https://quizlet.com/_gvbj1k
_____________ related to the ______ of cholinergic neu-
ronal activity
7. Memantine, an NMDA receptor antagonist, is often acetylcholinesterase in-
combined with an: hibitor in the treatment of
moderate to severe AD
8. A variety of medications have been developed for MS many of these treat-
to manage and address the relapsing patient, howev- ments are infusions re-
er: quiring professional ad-
ministration and supervi-
sion
9. Most of the pharmacological treatments of MS: modify and inhibit some
immune responses, thus
increasing the risk for in-
fections
10. A 75-year-old man has moderate Parkinson disease. B. Levodopa, carbidopa,
His tremors and bradykinesia are no longer respond- and entacapone
ing to anticholinergic treatment. Which combination
of antiparkinsonian drugs is an appropriate treatment
plan?
A. Amantadine, carbidopa, and entacapone
B. Levodopa, carbidopa, and entacapone
C. Pramipexole, carbidopa, and entacapone
D. Ropinirole, carbidopa, and selegiline
11. Which drug used in the management of Parkinson B. Bromocriptine
disease may cause vasospasm?
A. Amantadine
B. Bromocriptine
